Rezafungin acetate- Cidara Therapeutics

Drug Profile

Rezafungin acetate- Cidara Therapeutics

Alternative Names: Biafungin™; CD 101; CD 101 IV; CD 101 Topical; SP 3025

Latest Information Update: 03 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Seachaid Pharmaceuticals
  • Developer Cidara Therapeutics
  • Class Antifungals; Echinocandins; Small molecules
  • Mechanism of Action Glucan synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Candidiasis; Candidaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Candidiasis
  • Preclinical Aspergillosis
  • Discontinued Vulvovaginal candidiasis

Most Recent Events

  • 08 Nov 2017 Cidara Therapeutics plans a phase III trial for Candidiasis Worldwide in June 2018
  • 01 Aug 2017 Pharmacokinetics data from preclinical studies in Candidiasis released by Cidara Therapeutics
  • 22 Apr 2017 Pharmacodyamics data from preclinical trials in Aspergillosis and Candidiasis presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top